

ASX Announcement

2020 Annual General Meeting

Sydney Australia, 30 September 2020: Recce Pharmaceuticals Ltd (**ASX: RCE**) (**Company**), the company developing New Classes of Synthetic Anti-infectives, advises that the Annual General Meeting ("AGM") of the Company is scheduled for Thursday 19 November 2020.

Details of how and where the AGM will be held will be subject to COVID-19 restrictions, including any regulatory requirements that need to be adhered to by the Company. Further details of the AGM (which includes, any details of hybrid or virtual meeting facilities (if applicable)), will be confirmed once the AGM notice of meeting is despatched to shareholders of the Company.

Further to Listing Rule 3.13.1, Listing Rule 14.3 and Clause 14.3 of the Company's Constitution, nominations for election of directors at the AGM must be received no later than 8 October 2020.

This announcement has been approved for release by Recce Pharmaceuticals CEO.



ASX: RCE

Head Office: Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (02) 8075 4585 **F** +61 (02) 8075 4584

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of New Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.

Recce's anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE[®] 327 and RECCE[®] 435, and RECCE[®] 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.

Patented lead candidate RECCE[®] 327 has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Recce's new antibiotic compound, RECCE[®] 435, has been formulated for oral use.

The FDA has awarded RECCE[®] 327 *Qualified Infectious Disease Product* designation under the *Generating Antibiotic Initiatives Now* (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.

Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of RECCE[®] technologies targeting synergistic, unmet medical needs.

Executive Director

James Graham
Recce Pharmaceuticals Ltd
+61 (02) 8075 4585
james.graham@recce.com.au

Media and Investor Relations (AU)

Andrew Geddes
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au

Media and Investor Relations (USA)

Meredith Sosulski, PhD
LifeSci Communications
+1 929 469 3851
msosulski@lifescicomms.com

recce.com.au
ACN 124 849 065

